Ashland Inc. (ASH) Stock Analysis and Metrics

Ashland

NYSE: ASH

$66.42 ▼ -0.14 (-0.21%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap3,060.84

P/E0.00

P/S0.00

Div. Yield24,829.78

Total Debt (Qtr)1.37 Bn

Revenue Growth (1y) (Qtr)0.63

Add ratio to table…

About

Ashland Inc. is a global additives and specialty ingredients company with a conscious and proactive mindset for sustainability. Our common stock is listed on the New York Stock Exchange (“NYSE”) under the ticker symbol “ASH”. The terms “Ashland,” the “Company,” “we” and “our” used herein refer to Ashland Inc., a Delaware Corporation, and its predecessors, and its consolidated subsidiaries, except where the context indicates otherwise. The Company serves customers in a wide range of consumer and industrial markets including, architectural coatings, construction, energy, food and beverage, personal care and pharmaceutical. With approximately 2,900 employees worldwide, Ashland serves customers in more than 100 countries.

Ashland generates revenue by selling additives and specialty ingredients across its four reportable segments. The Life Sciences segment provides pharmaceutical and nutrition solutions such as controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, tablet binders, and additives for food and beverage applications. The Personal Care segment offers biofunctionals, preservatives, skin, sun, oral and hair care ingredients, as well as household cleaning products. The Specialty Additives segment supplies rheology and performance enhancing additives for architectural coatings, construction, energy, automotive and industrial applications. The Intermediates segment produces 1,4 butanediol and related derivatives used as chemical intermediates and process solvents. Revenue is derived from sales to customers in these markets.

The company operates through the following segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates.

• Life Sciences includes pharmaceuticals, nutrition, agricultural chemicals, diagnostic films and fine chemicals; its pharmaceutical solutions comprise controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers and tablet binders; its nutrition solutions provide thickeners, stabilizers, emulsifiers and additives that enhance mouthfeel, control moisture migration, reduce oil uptake and bind structured foods; customers are pharmaceutical, food, beverage, hospital and radiology manufacturers; the nutraceuticals business was divested in August 2024.

• Personal Care consists of biofunctionals, microbial protectants (preservatives), skin care, sun care, oral care, hair care and household solutions; it provides natural, nature derived, biodegradable and high performance ingredients for customer driven solutions that protect, renew, moisturize and revitalize skin and hair and deliver formulations for toothpaste, mouthwash, rinse, denture cleaning and tooth care; it supplies nature derived rheology ingredients, biodegradable surface wetting agents, performance encapsulates and specialty polymers for household, industrial and institutional cleaning products; customers are formulators at large multinational branded consumer products companies and smaller independent boutique companies.

• Specialty Additives offers rheology and performance enhancing additives for architectural coatings, construction, energy, automotive and various industrial markets; its solutions include coatings additives for architectural paints, finishes and lacquers, cement and gypsum based dry mortars, ready mixed joint compounds, synthetic plasters for commercial and residential construction and specialty materials for industrial applications; its products comprise rheology modifiers (cellulosic and associative thickeners), foam control agents, surfactants and wetting agents, pH neutralizers, advanced ceramics used in catalytic converters, environmental filters, ingredients that aid the manufacture of ceramic capacitors, plasma display panels and solar cells, ingredients for textile printing, thermoplastic metals and alloys for welding; these products improve functional outcomes through rheology modification and control, water retention, workability, adhesive strength, binding power, film formation, deposition, suspension and emulsification; customers include global paint manufacturers, electronics and automotive manufacturers, textile mills, the construction industry and welders.

• Intermediates is engaged in the production of 1,4 butanediol and related derivatives including n methylpyrrolidone; these chemicals serve as intermediates in the production of engineering polymers and polyurethanes and as specialty process solvents in electronics, agriculture, pharmaceuticals, water filtration membranes and other applications; BDO is also supplied to the Life Sciences, Personal Care and Specialty Additives segments as a raw material; key customers include Ashland’s Life Sciences, Personal Care and Specialty Additives segments, general industrial manufacturers, plastics and polymers producers, pharmaceutical companies, agricultural firms and producers of electronic components and systems; manufacturing takes place at a facility in Lima, Ohio with some derivatives produced at Life Sciences sites in Texas City, Texas and Calvert City, Kentucky; the segment markets and distributes its products in the Americas, Europe and Asia Pacific.

Ashland competes in a highly fragmented additives and specialty ingredients industry where participants vie on product performance and quality, price, availability, security of supply, responsiveness of product development with customers, customer service, industry knowledge and technical capability; several key competitors are larger than Ashland and possess greater financial resources which grants them additional operating and financial flexibility; the industry has grown more global as companies seek leadership positions beyond their home markets; many product lines face domestic and international competition due to consolidation, pricing pressures and competing technologies; Ashland leverages its brand and global scale to combine operational agility with disciplined investment in targeted areas while expanding beyond core technologies through differentiated new technology platforms that support the launch of new product lines and applications.

Ashland serves a diverse customer base that includes manufacturers of architectural coatings, construction materials, energy products, food and beverage items, personal care goods and pharmaceutical products; its customers range from large multinational corporations to independent boutique formulators; specific customer names are not disclosed in the filing but the company indicates it works with global paint makers, electronics and automotive producers, textile mills, welding firms, hospitals and radiology service providers.

Investment Thesis

▲ Bull case

Ashland's core consumer-facing businesses, particularly Life Sciences and Personal Care, continue to exhibit resilient end-market demand despite broader macroeconomic uncertainty, with Life Sciences delivering four consecutive quarters of volume gains in critical segments like injectables, tablet coatings, and high-purity excipients, driven by resilient pharma demand and ongoing adoption of differentiated new product introductions under its Innovate platform. Personal Care achieved broad-based portfolio growth across biofunctional actives, care ingredients, and microbial protection, with biofunctional actives delivering robust double-digit year-over-year growth and microbial protection gaining share following globalized investments, indicating that the company's focus on high-value, innovation-led applications is creating durable demand pockets less susceptible to cyclical downturns in end markets. This underlying demand stability is further supported by management's observation that recent softness in non-pharma nutrition within Life Sciences reflects customer order timing rather than fundamental market deterioration, with recent wins and ongoing commercial activity reinforcing confidence in a rebound in the second half of the fiscal year.
Ashland's innovation and globalization initiatives are not only gaining traction but are significantly exceeding internal targets, with Innovate already surpassing its full-year $15 million incremental sales target after just two quarters, delivering approximately $10 million in Q2 alone and taking cumulative year-to-date performance past the annual goal, fueled by strong adoption in high-purity pharma excipients and emerging contributions from GLP-1-related applications, while Globalize delivered double-digit year-over-year growth in the quarter with incremental sales ahead of plan, reflecting continued momentum from prior regional investments. These platforms are reinforced by scalable technology foundations such as transformed vegetable oil (TVO), super wet agents, and bioresorbable polymers, which are advancing into multiple end markets including personal care, coatings, and medical devices, with customer trials progressing and regulatory milestones being achieved, positioning Ashland to capitalize on secular trends in sustainability, biopharma delivery systems, and high-performance materials.
Operational challenges impacting near-term profitability, such as the Calvert City outage and Hopewell HEC scale-up delays, are explicitly characterized by management as internal, temporary, and within control, with Calvert City now back online and Hopewell showing sequential improvement in productivity and yield, while the company has reduced its overall cost base through prior structural actions like VP&D and small plant consolidation, which are lowering the structural cost base of its cellulosics platform and enhancing margin durability; importantly, the firm is not planning a broad inventory rebuild, instead focusing on specific product line normalization, which reduces working capital strain and supports cash generation, as evidenced by Q2 operating cash flow of $50 million (up from $9 million prior year) and ongoing free cash flow of $29 million, reflecting disciplined working capital management and reduced capex, providing financial flexibility to navigate near-term headwinds while investing in strategic priorities.

Ashland's core consumer-facing businesses, particularly Life Sciences and Personal Care, continue to exhibit resilient end-market demand despite broader macroeconomic uncertainty, with Life Sciences delivering four consecutive quarters of volume gains in critical segments like injectables, tablet coatings, and high-purity excipients, driven by resilient pharma demand and ongoing adoption of differentiated new product introductions under its Innovate platform. Personal Care achieved broad-based portfolio growth across biofunctional actives, care ingredients, and microbial protection, with biofunctional actives delivering robust double-digit year-over-year growth and microbial protection gaining share following globalized investments, indicating that the company's focus on high-value, innovation-led applications is creating durable demand pockets less susceptible to cyclical downturns in end markets. This underlying demand stability is further supported by management's observation that recent softness in non-pharma nutrition within Life Sciences reflects customer order timing rather than fundamental market deterioration, with recent wins and ongoing commercial activity reinforcing confidence in a rebound in the second half of the fiscal year.
Ashland's innovation and globalization initiatives are not only gaining traction but are significantly exceeding internal targets, with Innovate already surpassing its full-year $15 million incremental sales target after just two quarters, delivering approximately $10 million in Q2 alone and taking cumulative year-to-date performance past the annual goal, fueled by strong adoption in high-purity pharma excipients and emerging contributions from GLP-1-related applications, while Globalize delivered double-digit year-over-year growth in the quarter with incremental sales ahead of plan, reflecting continued momentum from prior regional investments. These platforms are reinforced by scalable technology foundations such as transformed vegetable oil (TVO), super wet agents, and bioresorbable polymers, which are advancing into multiple end markets including personal care, coatings, and medical devices, with customer trials progressing and regulatory milestones being achieved, positioning Ashland to capitalize on secular trends in sustainability, biopharma delivery systems, and high-performance materials.
Operational challenges impacting near-term profitability, such as the Calvert City outage and Hopewell HEC scale-up delays, are explicitly characterized by management as internal, temporary, and within control, with Calvert City now back online and Hopewell showing sequential improvement in productivity and yield, while the company has reduced its overall cost base through prior structural actions like VP&D and small plant consolidation, which are lowering the structural cost base of its cellulosics platform and enhancing margin durability; importantly, the firm is not planning a broad inventory rebuild, instead focusing on specific product line normalization, which reduces working capital strain and supports cash generation, as evidenced by Q2 operating cash flow of $50 million (up from $9 million prior year) and ongoing free cash flow of $29 million, reflecting disciplined working capital management and reduced capex, providing financial flexibility to navigate near-term headwinds while investing in strategic priorities.

▼ Bear case

Ashland's Specialty Additives segment continues to face structural headwinds beyond temporary disruptions, with flat year-over-year sales in Q2 reflecting not only pricing pressure and lapping of a difficult prior-year China comparison but also deliberate portfolio mix actions in construction volumes tied to network optimization and muted end-market demand, suggesting that weakness in this business may persist longer than management anticipates, particularly as the company acknowledges that any recovery in coatings is expected to be gradual and regionally uneven, and with Other end markets showing mixed performance where growth in Performance Specialties is offset by softer energy demand tied to customer-specific impacts in the Middle East, a region where Ashland has limited but non-negligible exposure (approximately 5% of sales), raising concerns about demand volatility in a geopolitically sensitive area despite claims of manageable impact.
Despite management's emphasis on pricing upside as a potential tailwind, the company has explicitly refrained from incorporating price increase benefits into its fiscal 2026 guidance, citing uncertainty in demand recovery in core markets like North America and Europe coatings, where customers remain prudent and no improvement is being seen, which implies that the midpoint of the $385 million to $400 million adjusted EBITDA guidance assumes neutral to negative price-cost dynamics in the near term, and with raw material and logistics costs trending higher due to geopolitical-driven volatility, the company's ability to recover inflation through pricing remains unproven and contingent on customer acceptance, creating a risk that margin pressure could persist if pricing actions lag cost increases or fail to achieve expected magnitude, especially given that energy-intensive inputs represent roughly 15% of sales and freight another 5%, creating a 20% cost exposure that, while partially mitigated by U.S.-sourced inputs, still leaves vulnerability to sustained input cost inflation.
The Intermediates segment operates at a stable but trough-level environment with BDO value chain sales down 5% year-over-year, and while management cites favorable U.S.-based natural gas and butane feedstock advantages relative to higher-cost European and Asian competitors, the segment's profitability remains highly dependent on external factors such as antidumping duties and reassessments of single-region sourcing, which, although potentially favorable in the long term, offer no near-term visibility for earnings improvement, and with captive BDO sales down approximately $1 million year-over-year due to Calvert City impacts and merchant sales pressured by modest pricing pressure and disciplined commercial actions, the business lacks clear catalysts for volume or margin expansion in the near term, leaving it as a drag on overall portfolio performance unless a meaningful uptick in derivatives demand occurs, which management acknowledges is uncertain and not reflected in current guidance.

Ashland's Specialty Additives segment continues to face structural headwinds beyond temporary disruptions, with flat year-over-year sales in Q2 reflecting not only pricing pressure and lapping of a difficult prior-year China comparison but also deliberate portfolio mix actions in construction volumes tied to network optimization and muted end-market demand, suggesting that weakness in this business may persist longer than management anticipates, particularly as the company acknowledges that any recovery in coatings is expected to be gradual and regionally uneven, and with Other end markets showing mixed performance where growth in Performance Specialties is offset by softer energy demand tied to customer-specific impacts in the Middle East, a region where Ashland has limited but non-negligible exposure (approximately 5% of sales), raising concerns about demand volatility in a geopolitically sensitive area despite claims of manageable impact.
Despite management's emphasis on pricing upside as a potential tailwind, the company has explicitly refrained from incorporating price increase benefits into its fiscal 2026 guidance, citing uncertainty in demand recovery in core markets like North America and Europe coatings, where customers remain prudent and no improvement is being seen, which implies that the midpoint of the $385 million to $400 million adjusted EBITDA guidance assumes neutral to negative price-cost dynamics in the near term, and with raw material and logistics costs trending higher due to geopolitical-driven volatility, the company's ability to recover inflation through pricing remains unproven and contingent on customer acceptance, creating a risk that margin pressure could persist if pricing actions lag cost increases or fail to achieve expected magnitude, especially given that energy-intensive inputs represent roughly 15% of sales and freight another 5%, creating a 20% cost exposure that, while partially mitigated by U.S.-sourced inputs, still leaves vulnerability to sustained input cost inflation.
The Intermediates segment operates at a stable but trough-level environment with BDO value chain sales down 5% year-over-year, and while management cites favorable U.S.-based natural gas and butane feedstock advantages relative to higher-cost European and Asian competitors, the segment's profitability remains highly dependent on external factors such as antidumping duties and reassessments of single-region sourcing, which, although potentially favorable in the long term, offer no near-term visibility for earnings improvement, and with captive BDO sales down approximately $1 million year-over-year due to Calvert City impacts and merchant sales pressured by modest pricing pressure and disciplined commercial actions, the business lacks clear catalysts for volume or margin expansion in the near term, leaving it as a drag on overall portfolio performance unless a meaningful uptick in derivatives demand occurs, which management acknowledges is uncertain and not reflected in current guidance.

Peer Comparison

Companies in the Specialty Chemicals

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LIN	Linde Plc	237.95 Bn	33.52	6.87	24.68 Bn
2	SHW	Sherwin Williams Co	78.17 Bn	30.07	3.27	11.70 Bn
3	ECL	Ecolab Inc.	76.02 Bn	30.01	4.73	8.24 Bn
4	APD	Air Products & Chemicals, Inc.	66.38 Bn	47.14	5.33	17.40 Bn
5	PPG	Ppg Industries Inc	26.02 Bn	3,717.41	1.61	7.83 Bn
6	LYB	LyondellBasell Industries N.V.	22.51 Bn	-28.53	0.76	11.45 Bn
7	SQM	Chemical & Mining Co Of Chile Inc	19.70 Bn	21.77	3.72	4.79 Bn
8	IFF	International Flavors & Fragrances Inc	19.51 Bn	-102.16	1.81	5.82 Bn

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password